Panobinostat(404950-80-7)

Multiple myeloma: On February 23, 2015, the FDA of the United States approved the HDAC inhibitor Panobinostat of Novartis, Switzerland, with the trade name of Farydak, for use in combination with bortezomib and dexamethasone. It was used to treat multiple myeloma that had been treated with bortezomib and an immunomodulator before but relapsed. Papistad is the first HDAC inhibitor drug approved by FDA for the treatment of multiple myeloma.

Biological activity: Panobinostat (LBH589, NVP-LBH589) is a new type of broad-spectrum HDAC inhibitor, with IC50 of 5 nM in cell-free test. Panobiostat (LBH589) can induce autophagy and apoptosis. Panobiostat can effectively destroy the incubation period of HIV in the body. Phase3。